The Filing Desk

Keros Therapeutics vs Ligand Pharmaceuticals

Keros Therapeutics KROS · Ligand Pharmaceuticals LGND · Biotechnology

Ligand Pharmaceuticals reported revenue of $268 million in fiscal 2025, about the same as Keros Therapeutics' $244 million in fiscal 2025. Keros Therapeutics had an operating margin of 27.7%, against 15.3% at Ligand Pharmaceuticals. Free cash flow was $106 million at Keros Therapeutics and $49 million at Ligand Pharmaceuticals.

Side by side

Keros TherapeuticsLigand Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$244M$268M
Revenue growth—60.4%
Revenue growth a year, last 5 years—10.4%
Gross margin——
Operating margin27.7%15.3%
Net margin35.7%46.4%
Free cash flow$106M$49M
Free cash flow margin43.5%18.2%
Return on capital—4.9%
Net debt to EBITDA—−3.8x
Dividends and buybacks$375M$15M
Change in diluted share count1.1%11.0%
Last close$11.39$286.94
P/E at the last close—124.8×
Insider trades, last 12 monthsbought $75,770, sold $506,996sold $35.0 million
Piotroski F-score—5 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Keros TherapeuticsLigand Pharmaceuticals
Operating margin
Percent of revenue
Keros TherapeuticsLigand Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Keros TherapeuticsLigand Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Keros Therapeutics and Ligand Pharmaceuticals pages.